Phase 3 Clinical Trials With Primary Completion Dates in September 2026
This is a list of Phase 3 trials with primary completion dates in September 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALKS | Alkermes plc | 2026-09-01 | Phase 3 | NCT05303064 | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder |
| ARDX | Ardelyx, Inc. | 2026-09-01 | Phase 3 | NCT05643534 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
| AVIR | Atea Pharmaceuticals, Inc. | 2026-09-01 | Phase 3 | NCT06868264 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV |
| CLRPF | Clarity Pharmaceuticals Ltd | 2026-09-01 | Phase 3 | NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
| IRON | Disc Medicine, Inc. | 2026-09-01 | Phase 3 | NCT06910358 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) |
| LLY | Eli Lilly and Company | 2026-09-01 | Phase 3 | NCT06339008 | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) |
| SUPN | Supernus Pharmaceuticals, Inc. | 2026-09-01 | Phase 3 | NCT02736656 | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) |
| VNDA | Vanda Pharmaceuticals Inc. | 2026-09-01 | Phase 3 | NCT04652882 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |